Laurie H. Sehn
劳里·塞恩
MD, MPH
Clinical Professor and Lymphoma Disease Site Leader临床教授兼淋巴瘤疾病研究方向负责人
👥Biography 个人简介
Professor Laurie Sehn is one of North America's most influential lymphoma clinicians and clinical trialists, with a particular focus on follicular lymphoma outcomes, prognostic factors, and novel therapies. She is internationally recognized for her work defining the POD24 (progression of disease within 24 months) criterion as a high-risk prognosticator in follicular lymphoma and for her leadership of the GADOLIN trial comparing obinutuzumab-bendamustine versus rituximab-bendamustine in rituximab-refractory follicular lymphoma. Sehn is a past president of the Canadian Hematology Society and sits on multiple international lymphoma guideline committees, including NCCN and LRF scientific advisory boards.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
POD24 as a Prognostic Biomarker in Follicular Lymphoma
Co-led the analysis establishing that disease progression within 24 months (POD24) of first-line chemoimmunotherapy identifies a high-risk subset of follicular lymphoma patients with dramatically inferior overall survival, creating a new standard endpoint for FL clinical trials and informing risk-adapted treatment strategies.
GADOLIN Trial — Rituximab-Refractory Follicular Lymphoma
Contributed to the GADOLIN phase III trial demonstrating that obinutuzumab plus bendamustine followed by obinutuzumab maintenance significantly improved progression-free survival in rituximab-refractory indolent lymphoma, leading to FDA approval of this regimen and establishing a path for patients who fail first-line R-based therapy.
Real-World Evidence in Follicular Lymphoma Outcomes
Built a world-renowned real-world evidence program through BC Cancer's population-based registry, producing landmark analyses of rituximab-bendamustine versus R-CHOP/R-CVP outcomes in the population setting and informing provincial treatment guidelines across Canada.
Representative Works 代表性著作
Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration
Journal of Clinical Oncology (2017)
Landmark study establishing immunological correlates of the POD24 adverse prognostic endpoint in follicular lymphoma.
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN)
The Lancet Oncology (2016)
Phase III trial leading to FDA approval of obinutuzumab for rituximab-refractory follicular lymphoma.
Comparative effectiveness of R-CHOP versus R-bendamustine as first-line therapy in follicular lymphoma: a population-based study
Blood Advances (2020)
Population-based real-world analysis from BC Cancer comparing first-line chemoimmunotherapy regimens in follicular lymphoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-20 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 劳里·塞恩 的研究动态
Follow Laurie H. Sehn's research updates
留下邮箱，当我们发布与 Laurie H. Sehn（BC Cancer — Vancouver Centre / University of British Columbia）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment